Realm Therapeutics   Report issue

For profit Phase 2
Founded: Malvern PA United States (1996)
Status: Acquired by ESSA Pharmaceuticals (2019)

Organization Overview

First Clinical Trial
2009
NCT00586729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PuriCore, Inc. | Realm | Realm Therapeutics | Realm Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

hypochlorous acid (2 trials)

muromonab cd3 (Orthoclone OKT3) (1 trial)

Drugs in Other Trials (1)

mafenide acetate (sulfamylon) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 2)

Conjunctivitis, Allergic (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3